ALG-170675 — other
Q3 2026
Amoytop's receipt of IND approval in China for ALG-170675 triggered a $3M milestone payment to Aligos, which is expected to be received in Q3 2026.Source filing
ALGS biotech catalysts & pipeline
ALIGOS THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
pevifoscorvir sodium — Interim data
H2 2026
The second interim analysis is expected in the second half of 2026.Source filing
pevifoscorvir sodium — Topline data
Q3 2027
As we look ahead to topline data from the B-SUPREME study which is expected in late Q3 next year, we remain confident that our differentiated pipeline has the potential to meaningfully reduce the burden of end-stage liver disease and liver cancer, the main goal of chronic HBV infection treatment.Source filing